PRESS RELEASE
News
-
-
PRESS RELEASE
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
OSE Immunotherapeutics reports positive results from Combi-TED Phase 2 trial with Tedopi® in metastatic NSCLC. Study to be presented at ESMO 2026. KOL webcast scheduled -
PRESS RELEASE
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatique
OSE Immunotherapeutics annonce des résultats positifs de l'étude de Phase 2 Combi-TED de Tedopi dans le cancer du poumon non à petites cellules métastatique, présentés au congrès annuel de l'ESMO. Webcast prévu avec des experts internationaux -
-
-
-
-
PRESS RELEASE
DKSH to Establish a Healthcare Platform in the Middle East and Scale Up Capabilities With the Acquisition of NewBridge Pharmaceuticals
DKSH Management Ltd. to establish a healthcare platform in the Middle East and North Africa (MENA) by acquiring NewBridge Pharmaceuticals for USD 390 million. The acquisition expands DKSH's healthcare capabilities and geographic footprint -
PRESS RELEASE
Centiel confirms USD 51.4 million U.S. purchase order, bringing U.S. order backlog to USD 60.1 million for planned delivery in 2027
Centiel confirms USD 51.4 million U.S. purchase order from Neo Critical Power LLC, increasing U.S. order backlog to USD 60.1 million for 2027 delivery, signaling growth phase -
